CD9 and plasma cell myeloma: Transfection of myeloma cell lines with CD9 also increases their sensitivity to the proteosome inhibitor bortezomib, which is frequently used in the treatment of myeloma, suggesting that loss of CD9 can influence drug resistance (Hu et al., 2014).